TY - JOUR AU - Druker, B. J. AU - Tamura, S. AU - Buchdunger, E. PY - 1996 DA - 1996// TI - Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells JO - Nat Med VL - 2 UR - https://doi.org/10.1038/nm0596-561 DO - 10.1038/nm0596-561 ID - Druker1996 ER - TY - JOUR AU - Buchdunger, E. AU - Cioffi, C. L. AU - Law, N. PY - 2000 DA - 2000// TI - Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors JO - J Pharmacol Exp Ther VL - 295 ID - Buchdunger2000 ER - TY - JOUR AU - Heinrich, M. C. AU - Griffith, D. J. AU - Druker, B. J. PY - 2000 DA - 2000// TI - Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor JO - Blood VL - 96 ID - Heinrich2000 ER - TY - JOUR AU - van Oosterom, A. T. AU - Judson, I. AU - Verweij, J. PY - 2001 DA - 2001// TI - Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study JO - Lancet VL - 358 UR - https://doi.org/10.1016/S0140-6736(01)06535-7 DO - 10.1016/S0140-6736(01)06535-7 ID - van Oosterom2001 ER - TY - STD TI - van Oosterom AT, Judson I, Verweij J, et al.: Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.Eur J Cancer38(Suppl 5):S83–7. ID - ref5 ER - TY - JOUR AU - Verweij, J. AU - van Oosterom, A. AU - Blay, J. Y. PY - 2003 DA - 2003// TI - Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study JO - Eur J Cancer VL - 39 UR - https://doi.org/10.1016/S0959-8049(02)00836-5 DO - 10.1016/S0959-8049(02)00836-5 ID - Verweij2003 ER - TY - JOUR AU - Demetri, G. D. AU - von Mehren, M. AU - Blanke, C. D. PY - 2002 DA - 2002// TI - Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors JO - N Engl J Med VL - 347 UR - https://doi.org/10.1056/NEJMoa020461 DO - 10.1056/NEJMoa020461 ID - Demetri2002 ER - TY - JOUR AU - Verweij, J. AU - Casali, P. G. AU - Zalcberg, J. PY - 2004 DA - 2004// TI - Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial JO - Lancet VL - 364 UR - https://doi.org/10.1016/S0140-6736(04)17098-0 DO - 10.1016/S0140-6736(04)17098-0 ID - Verweij2004 ER - TY - JOUR AU - Van Glabbeke, M. AU - Verweij, J. AU - Casali, P. G. PY - 2005 DA - 2005// TI - Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study JO - J Clin Oncol VL - 23 UR - https://doi.org/10.1200/JCO.2005.11.601 DO - 10.1200/JCO.2005.11.601 ID - Van Glabbeke2005 ER - TY - JOUR AU - Kerkela, R. AU - Grazette, L. AU - Yacobi, R. PY - 2006 DA - 2006// TI - Cardiotoxicity of the cancer therapeutic agent imatinib mesylate JO - Nat Med VL - 12 UR - https://doi.org/10.1038/nm1446 DO - 10.1038/nm1446 ID - Kerkela2006 ER - TY - JOUR AU - Perik, P. J. AU - Rikhof, B. AU - de Jong, F. A. PY - 2008 DA - 2008// TI - Results of plasma N-terminal pro B-type natriuretic peptide and cardiac troponin monitoring in GIST patients do not support the existence of imatinib-induced cardiotoxicity JO - Ann Oncol VL - 19 UR - https://doi.org/10.1093/annonc/mdm468 DO - 10.1093/annonc/mdm468 ID - Perik2008 ER - TY - JOUR AU - Demetri, G. D. AU - von Mehren, M. AU - Blanke, C. D. AU - Van den Abbeele, A. D. AU - Eisenberg, B. AU - Roberts, P. J. AU - Heinrich, M. C. AU - Tuveson, D. A. AU - Singer, S. AU - Janicek, M. AU - Fletcher, J. A. AU - Silverman, S. G. AU - Silberman, S. L. AU - Capdeville, R. AU - Kiese, B. AU - Peng, B. AU - Dimitrijevic, S. AU - Druker, B. J. AU - Corless, C. AU - Fletcher, C. D. AU - Joensuu, H. PY - 2002 DA - 2002// TI - Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors JO - N Engl J Med VL - 347 UR - https://doi.org/10.1056/NEJMoa020461 DO - 10.1056/NEJMoa020461 ID - Demetri2002 ER - TY - JOUR AU - Verweij, J. AU - Casali, P. G. AU - Zalcberg, J. AU - LeCesne, A. AU - Reichardt, P. AU - Blay, J. Y. AU - Issels, R. AU - van Oosterom, A. AU - Hogendoorn, P. C. AU - Van Glabbeke, M. AU - Bertulli, R. AU - Judson, I. PY - 2004 DA - 2004// TI - Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial JO - Lancet VL - 364 UR - https://doi.org/10.1016/S0140-6736(04)17098-0 DO - 10.1016/S0140-6736(04)17098-0 ID - Verweij2004 ER - TY - JOUR AU - Blanke, C. D. AU - Rankin, C. AU - Demetri, G. D. AU - Ryan, C. W. AU - von Mehren, M. AU - Benjamin, R. S. AU - Raymond, A. K. AU - Bramwell, V. H. AU - Baker, L. H. AU - Maki, R. G. AU - Tanaka, M. AU - Hecht, J. R. AU - Heinrich, M. C. AU - Fletcher, C. D. AU - Crowley, J. J. AU - Borden, E. C. PY - 2008 DA - 2008// TI - Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033 JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2007.13.4452 DO - 10.1200/JCO.2007.13.4452 ID - Blanke2008 ER - TY - JOUR AU - Debiec-Rychter, M. AU - Sciot, R. AU - Le Cesne, A. AU - Schlemmer, M. AU - Hohenberger, P. AU - van Oosterom, A. T. AU - Blay, J. Y. AU - Leyvraz, S. AU - Stul, M. AU - Casali, P. G. AU - Zalcberg, J. AU - Verweij, J. AU - Van Glabbeke, M. AU - Hagemeijer, A. AU - Judson, I. PY - 2006 DA - 2006// TI - EORTC Soft Tissue and Bone Sarcoma Group; The Italian Sarcoma Group; Australasian Gastrointestinal Trials Group. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours JO - Eur J Cancer VL - 42 UR - https://doi.org/10.1016/j.ejca.2006.01.030 DO - 10.1016/j.ejca.2006.01.030 ID - Debiec-Rychter2006 ER -